INVESTORS

Press Releases

Press Releases

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
June 28, 2021
DURHAM, N.C. & STAMFORD, Conn. --(BUSINESS WIRE)--Jun. 28, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc....
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer
May 27, 2021
DURHAM, N.C. --(BUSINESS WIRE)--May 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief...
Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting
May 19, 2021
Precision to Provide PBCAR0191 Update via Hosted Conference Call and Webcast on Friday, June 4, 2021 DURHAM, N.C. --(BUSINESS WIRE)--May 19, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies,...
Displaying 11 - 20 of 37

Investors

Investor Tools